Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
16.70
+1.77 (11.86%)
Apr 1, 2026, 4:00 PM EDT - Market closed

Avalo Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Apr '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
38133678748192
Market Cap Growth
371.00%332.09%966.44%-84.65%-75.21%-3.16%
Enterprise Value
282.66237.86-56.74-0.1253.77169.99
Last Close Price
16.7018.167.439.101209.604896.00
PE Ratio
--3.11-0.36-0.08-1.14-2.05
PS Ratio
6450.295698.16176.433.792.6335.52
PB Ratio
3.724.050.581.00-4.358.31
P/TBV Ratio
2.702.930.420.35-30.78-
P/FCF Ratio
--6.53-1.59-0.24-1.77-2.70
P/OCF Ratio
--6.53-1.59-0.24-1.78-2.70
EV/Sales Ratio
4790.824031.45-128.66-0.062.9831.49
EV/EBITDA Ratio
--3.280.830.00-1.44-2.11
EV/EBIT Ratio
--3.260.830.00-1.44-2.07
EV/FCF Ratio
--4.621.160.00-2.00-2.39
Debt / Equity Ratio
-000-1.781.42
Debt / EBITDA Ratio
-----0.52-0.41
Debt / FCF Ratio
-----0.72-0.46
Net Debt / Equity Ratio
-1.18-1.18-1.01-1.01-0.57-0.94
Net Debt / EBITDA Ratio
1.361.361.970.27-0.170.27
Net Debt / FCF Ratio
1.911.912.740.24-0.230.31
Asset Turnover
0.000.000.010.070.320.09
Inventory Turnover
---128.40118.4172.73
Quick Ratio
7.607.6019.331.640.682.99
Current Ratio
8.148.1419.961.820.743.11
Return on Equity (ROE)
-72.43%-72.43%-50.06%1747.11%-684.77%-354.08%
Return on Assets (ROA)
-54.70%-54.70%-80.05%-100.67%-65.97%-132.20%
Return on Invested Capital (ROIC)
-989.69%-989.69%-741.24%-419.07%-761.49%-981.77%
Return on Capital Employed (ROCE)
-58.98%-58.98%-85.56%-197.99%-104.61%-184.87%
Earnings Yield
-20.56%-32.16%-281.43%-1248.13%-87.88%-48.77%
FCF Yield
-13.52%-15.31%-63.05%-422.68%-56.48%-37.03%
Buyback Yield / Dilution
-78.82%-78.82%-2599.19%0.00%--
Total Shareholder Return
-78.82%-78.82%-2599.19%0.00%--
Updated Mar 23, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q